Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 2 Interventional Results available

Study to Evaluate Vadadustat for Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Who Are Hyporesponsive to Erythropoiesis Stimulating Agents

ClinicalTrials.gov ID: NCT03140722

Public ClinicalTrials.gov record NCT03140722. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 7:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase 2, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Treatment of Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Who Are Hyporesponsive to Erythropoiesis Stimulating Agents

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a Phase 2, randomized, open-label study to evaluate vadadustat versus epoetin alfa for the treatment of anemia in subjects with Dialysis-dependent Chronic Kidney Disease (DD-CKD) who are hyporesponsive to erythropoiesis stimulating agents (ESAs.)

Study identification

NCT ID
NCT03140722
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
Akebia Therapeutics
Industry
Enrollment
2 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 2, 2017 (Actual)
Primary completion
Mar 21, 2018 (Actual)
Completion
Mar 21, 2018 (Actual)
Last update posted
Feb 21, 2021

2017 – 2018

United States locations

U.S. sites
18
U.S. states
9
U.S. cities
18
Facility City State ZIP Site status
Research Site Bakersfield California 93309 —
Research Site Elk Grove California 95758 —
Research Site Encino California 91316 —
Research Site Escondido California 92025 —
Research Site Lynwood California 90262 —
Research Site San Diego California 92115 —
Research Site San Luis Obispo California 93401 —
Research Site Waterbury Connecticut 06708 —
Research Site Miami Florida 33183 —
Research Site Orlando Florida 32804 —
Research Site Statesboro Georgia 30458 —
Research Site Detroit Michigan 48224 —
Research Site The Bronx New York 10473 —
Research Site Philadelphia Pennsylvania 19106 —
Research Site El Paso Texas 79915 —
Research Site Houston Texas 77070 —
Research Site Newport News Virginia 23605 —
Research Site Norfolk Virginia 23502 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03140722, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 21, 2021 · Synced Oct 25, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT03140722 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →